December 2nd 2023
“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Can remote patient monitoring help combat the staffing shortage?
November 22nd 2023"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
November 21st 2023"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.